Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD

Blood (2019) 134 (Supplement_1): 4071.

https://doi.org/10.1182/blood-2019-124904

Published: 2019

Journal Articles

Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

Laura K Schoch, MS, CRNP, Ivan Borrello, MD, Ephraim J. Fuchs, MD, Javier Bolanos-Meade, MD, Jeffrey Sean Huo, MD PhD, Ivana Gojo, MD, Nina Wagner-Johnston, MD, Gabrielle T Prince, MD, Shannon R. McCurdy, MD, B. Douglas Smith, MD, Amy E. DeZern, MD MHS, Margaret M. Showel, MD, David Loeb, MD PhD, Aziza T. Shad, MD, Richard J Jones, MD, Richard F. Ambinder, MD PhD, Douglas Gladstone, MD

Blood (2016) 128 (22): 4571.

https://doi.org/10.1182/blood.V128.22.4571.4571

Published: 2016

Journal Articles

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Colleen E. Annesley, MD, Amy S. Duffield, MD PhD, Rachel E. Rau, MD, Gregory McCarty, Daniel Magoon, Li Li, MD PhD, Vicki Huff, PhD, Donald Small, MD PhD, David Loeb, MD PhD, Patrick Brown, MD

Blood (2015) 126 (23): 312.

https://doi.org/10.1182/blood.V126.23.312.312

Published: 2015

Journal Articles

Leukemogenic Wilms Tumor 1 (WT1) Mutations Enhance Progenitor Self Renewal, Inhibit Terminal Myeloid Differentiation, and Influence Survival in a Mouse Model

Colleen E. Annesley, MD, Rachel E. Rau, MD, Daniel Magoon, BS, Gregory McCarty, David Loeb, MD PhD, Patrick Brown, MD

Blood (2014) 124 (21): 3572.

https://doi.org/10.1182/blood.V124.21.3572.3572

Published: 2014

Journal Articles

Oncogenic Wilms Tumor 1 (WT1) Mutation Augments Hematopoietic Progenitor Cell Clonogenicity and Promotes Expansion Of The Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment: Implications For WT1-Mediated Leukemogenesis

Colleen E. Annesley, MD, Rachel E. Rau, MD, Daniel Magoon, David Loeb, MD, PhD, Patrick Brown, MD

Blood (2013) 122 (21): 1269.

https://doi.org/10.1182/blood.V122.21.1269.1269

Published: 2013

Journal Articles

Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation

Nirali N Shah, MD, Michael J. Borowitz, MD, PhD, Nancy Robey, PA, Christopher Gamper, MD, PhD, Heather J. Symons, MD, MHS, David Loeb, MD, PhD, Alan S Wayne, MD, Allen R. Chen, MD, PhD, MHS

Blood (2012) 120 (21): 4205.

https://doi.org/10.1182/blood.V120.21.4205.4205

Published: 2012

Journal Articles

Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation

Nirali N Shah, MD, Michael J. Borowitz, MD, PhD, Seth M. Steinberg, PhD, Mary Lefell, PhD, Nancy Robey, PA, Christopher Gamper, MD, PhD, Heather J. Symons, MD, MHS, David Loeb, MD, PhD, Alan S Wayne, MD, Allen R. Chen, MD, PhD, MHS

Blood (2012) 120 (21): 4206.

https://doi.org/10.1182/blood.V120.21.4206.4206

Published: 2012

Journal Articles

A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies and Post-Transplant Relapse

Nirali N Shah, MD, David Loeb, MD, PhD, Hahn Khuu, MD, David Stroncek, MD, Mark Raffeld, MD, Cindy Delbrook, RN, Kelly Richards, RN, Kristin Baird, MD, Jason Levine, MD, Susan F. Leitman, MD, Crystal L Mackall, MD, Terry J Fry, MD, Alan S Wayne, MD

Blood (2011) 118 (21): 3055.

https://doi.org/10.1182/blood.V118.21.3055.3055

Published: 2011

Journal Articles

Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects

Colleen E. Annesley, MD, Rachel E. Rau, MD, Gregory McCarty, Daniel Magoon, Edward Allan R. Sison, MD, David Loeb, MD, PhD, Patrick A. Brown, MD

Blood (2011) 118 (21): 2437.

https://doi.org/10.1182/blood.V118.21.2437.2437

Published: 2011

Journal Articles

Plerixafor Is Highly Effective for the Mobilization of Autologous PBSC for Transplant in Children Failing to Mobilize by Conventional Means: International Experience with 40 Children From 19 Centers

Blood (2011) 118 (21): 1931.

https://doi.org/10.1182/blood.V118.21.1931.1931

Published: 2011

NARROW

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Leukemogenic Wilms Tumor 1 (WT1) Mutations Enhance Progenitor Self Renewal, Inhibit Terminal Myeloid Differentiation, and Influence Survival in a Mouse Model

Oncogenic Wilms Tumor 1 (WT1) Mutation Augments Hematopoietic Progenitor Cell Clonogenicity and Promotes Expansion Of The Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment: Implications For WT1-Mediated Leukemogenesis

Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation

Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation

A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies and Post-Transplant Relapse

Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects

Plerixafor Is Highly Effective for the Mobilization of Autologous PBSC for Transplant in Children Failing to Mobilize by Conventional Means: International Experience with 40 Children From 19 Centers

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only